PMID- 26277907
OWN - NLM
STAT- MEDLINE
DCOM- 20170103
LR  - 20211203
IS  - 1532-8414 (Electronic)
IS  - 1071-9164 (Linking)
VI  - 22
IP  - 4
DP  - 2016 Apr
TI  - Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 
      2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure.
PG  - 249-55
LID - S1071-9164(15)00669-7 [pii]
LID - 10.1016/j.cardfail.2015.07.017 [doi]
AB  - BACKGROUND: B-Type natriuretic peptides (BNP) and cardiac troponin T (cTnT) 
      predict cardiovascular events in heart failure (HF) patients, but additional 
      refinement in risk stratification may be possible by targeting pathways leading 
      to fibrosis. We aimed to assess the value of serial measurements of soluble 
      suppression of tumorigenicity 2 (sST2) and galectin-3 to identify risk for 
      adverse pathophysiologic processes. METHODS: New York Heart Association (NYHA) 
      functional class III-IV HF patients (n = 180; LVEF </=40%) were prospectively 
      evaluated with biomarkers collected every 3 months over 2 years and analyzed 
      regarding a primary end point of death/cardiac transplantation and a secondary 
      end point of HF-related hospitalization or death/transplantation. RESULTS: 
      Time-dependent univariate analyses demonstrated that elevations of sST2 (>/=49.3 
      ng/mL male, >/=33.5 ng/mL female) and galectin-3 (>/=22.1 ng/mL) were predictive of 
      the primary and secondary end points. In multivariate models adjusted for BNP, 
      cTnT, and clinical variables, sST2 but not galectin-3 remained an independent 
      predictor (hazard ratio 3.22, 95% confidence interval 1.76-5.89; P < .001). With 
      serial measurements, only sST2 demonstrated incremental value in reclassifying 
      patients to higher risk. CONCLUSIONS: Serial monitoring of sST2 (indicating 
      myocardial fibrosis and remodeling) and cTnT (reflecting myocardial injury) 
      identifies highest-risk HF outpatients and may be valuable to guide patient 
      tailored therapy during follow-up evaluations. Serial galectin-3 monitoring in 
      ambulatory HF patients may not be of benefit.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Miller, Wayne L
AU  - Miller WL
AD  - Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, 
      Rochester, Minnesota. Electronic address: miller.wayne@mayo.edu.
FAU - Saenger, Amy K
AU  - Saenger AK
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, 
      Minnesota.
FAU - Grill, Diane E
AU  - Grill DE
AD  - Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, 
      Minnesota.
FAU - Slusser, Joshua P
AU  - Slusser JP
AD  - Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, 
      Minnesota.
FAU - Bayes-Genis, Antoni
AU  - Bayes-Genis A
AD  - University Hospital Germans Trias i Pujol, Barcelona, Spain.
FAU - Jaffe, Allan S
AU  - Jaffe AS
AD  - Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, 
      Rochester, Minnesota; Department of Laboratory Medicine and Pathology, Mayo 
      Clinic, Rochester, Minnesota.
LA  - eng
PT  - Journal Article
DEP - 20150814
PL  - United States
TA  - J Card Fail
JT  - Journal of cardiac failure
JID - 9442138
RN  - 0 (Biomarkers)
RN  - 0 (Blood Proteins)
RN  - 0 (Galectin 3)
RN  - 0 (Galectins)
RN  - 0 (IL1RL1 protein, human)
RN  - 0 (Interleukin-1 Receptor-Like 1 Protein)
RN  - 0 (LGALS3 protein, human)
SB  - IM
CIN - J Card Fail. 2016 Apr;22(4):263-4. PMID: 26923642
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/blood
MH  - Blood Proteins
MH  - Chronic Disease
MH  - Female
MH  - Follow-Up Studies
MH  - Galectin 3/*blood
MH  - Galectins
MH  - Heart Failure/*blood/*diagnosis
MH  - Humans
MH  - Interleukin-1 Receptor-Like 1 Protein/*blood
MH  - Male
MH  - Middle Aged
MH  - *Monitoring, Ambulatory/methods
MH  - Prognosis
MH  - Prospective Studies
OTO - NOTNLM
OT  - Serial biomarkers
OT  - chronic heart failure
OT  - galectin-3
OT  - sST2
EDAT- 2015/08/19 06:00
MHDA- 2017/01/04 06:00
CRDT- 2015/08/18 06:00
PHST- 2015/02/13 00:00 [received]
PHST- 2015/07/23 00:00 [revised]
PHST- 2015/07/31 00:00 [accepted]
PHST- 2015/08/18 06:00 [entrez]
PHST- 2015/08/19 06:00 [pubmed]
PHST- 2017/01/04 06:00 [medline]
AID - S1071-9164(15)00669-7 [pii]
AID - 10.1016/j.cardfail.2015.07.017 [doi]
PST - ppublish
SO  - J Card Fail. 2016 Apr;22(4):249-55. doi: 10.1016/j.cardfail.2015.07.017. Epub 
      2015 Aug 14.